Abstracts tagged "Genomics and Proteomics"

Abstract Number: 0100 • ACR Convergence 2025
Therapeutic Modulation of NAD+ Metabolism in Inflammatory Rheumatic Disorders by TNFi and NAD+ Precursors
Beatriz Vellón-García¹, Gema Dolores García-Delgado², Adrián Llamas Urbano³, Yas Hanaee³, Pedro Ortiz Buitrago⁴, Christian Merlo⁵, Maria del carmen abalos-aguilera⁵, julio Manuel Martinez Moreno⁶, Iván Arias de la Rosa⁷, María Dolores López-Montilla⁸, Rafaela Ortega-Castro⁹, Jerusalén Calvo¹⁰, Lourdes Ladehesa¹¹, Clementina López Medina¹², María Ángeles Puche-Larrubia¹³, Nuria Barbarroja¹⁴, Eduardo Collantes estévez¹⁵, Alejandro Escudero-contreras⁵, Chary López pedrera¹⁶, Jose manuel Villalba¹⁷ and Carlos Pérez Sánchez¹⁸, ¹Rheumatology Service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/University of Cordoba/ Reina Sofia University Hospital, Córdoba, Spain/Department of Cell Biology, Physiology and Immunology, Maimonides Institute of Biomedical Research of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Córdoba, Córdoba, Spain, Cordoba, Spain, ²Rheumatology Service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/University of Cordoba/ Reina Sofia University Hospital, Córdoba, Spain/Department of Cell Biology, Physiology and Immunology, Maimonides Institute of Biomedical Research of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Cordoba, Cordoba, Spain., Cordoba, Spain, ³Cobiomic Bioscience SL. EBT University of Cordoba/IMIBIC, Cordoba, Spain., Cordoba, Spain, ⁴Maimonides Institute of Biomedical Research of Córdoba (IMIBIC), Cordoba, Andalucia, Spain, ⁵Rheumatology Service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/University of Cordoba/ Reina Sofia University Hospital, Córdoba, Spain, Cordoba, Spain, ⁶Cobiomic Bioscience SL. EBT University of Cordoba/IMIBIC, Cordoba, Spain, Cordoba, Spain, ⁷IMIBIC/FIBICO/Department of Gastroenterology, Hospital General de Tomelloso, Tomelloso; Instituto de Investigación Sanitaria de Castilla-La Mancha (IDISCAM), Toledo, Spain; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd) Toledo, Spain., Córdoba, Spain, ⁸Rheumatology Department, Reina Sofía University Hospital, Cordoba/IMIBIC/University of Cordoba., CORDOBA, Spain, ⁹Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Andalucia, Spain, ¹⁰IMIBIC / Reina Sofia Hospital / University of Cordoba, Córdoba, Spain, ¹¹IMIBIC-Reina Sofia Hospital-University of Cordoba, Cordoba, Spain, Cordoba, Spain, ¹²Department of Medicine, Hospital Universitario Reina Sofia, University of Cordoba, IMIBIC, Cordoba, Spain, ¹³Reina Sofia University Hospital, Granada, Spain, ¹⁴Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain/CobiomicBioscience S.l, Cordoba, Spain, Cordoba, Spain, ¹⁵Maimonides Institute for Biomedical Research of Córdoba (IMIBIC) / Department of Medical and Surgical Sciences, Faculty of Medicine, University of Córdoba, Spain, Cordoba, Spain, ¹⁶Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Spain, ¹⁷Department of Cell Biology, Physiology and Immunology, Maimonides Institute of Biomedical Research of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Cordoba, Cordoba, Spain, Cordoba, Spain, ¹⁸Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain/ CobiomicBioscience S.l, Cordoba, Spain, Cordoba, Spain
Background/Purpose: This study aims to:Characterize the NAD+ metabolome in CIRDs and their association with clinical traits.Evaluate the impact of TNFi therapy on NAD+ metabolome alterations.Test…
Abstract Number: 2599 • ACR Convergence 2025
Identification of a New Pathogenic Axis in Antiphospholipid Syndrome Linking Antiphospholipid Antibodies, Liver Function, and Circulating Proatherogenic Metabolites
Beatriz Vellón-García¹, Sagrario Corrales-Díaz-Flores², MARIA ANGELES AGUIRRE ZAMORANO³, Ismael Sanchez-Pareja³, Laura muñoz-Barrera³, Tomás Cerdó³, Pedro Seguí-Azpilcueta⁴, Christian Merlo², Maria del carmen abalos-aguilera², Nuria Barbarroja⁵, Rafaela Ortega-Castro⁶, José-Antonio Gonzalez-Reyes⁷, Alejandro Escudero-contreras², Chary López pedrera⁸, Jose manuel Villalba⁹ and Carlos Pérez Sánchez¹⁰, ¹Rheumatology Service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/University of Cordoba/ Reina Sofia University Hospital, Córdoba, Spain/Department of Cell Biology, Physiology and Immunology, Maimonides Institute of Biomedical Research of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Córdoba, Córdoba, Spain, Cordoba, Spain, ²Rheumatology Service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/University of Cordoba/ Reina Sofia University Hospital, Córdoba, Spain, Cordoba, Spain, ³Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Córdoba, Spain, ⁴Radiology Service, Reina Sofia Hospital/Maimonides Institute for Research in Biomedicine of Cordoba/University of Cordoba, Spain, Córdoba, United Kingdom, ⁵Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain/CobiomicBioscience S.l, Cordoba, Spain, Cordoba, Spain, ⁶Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Andalucia, Spain, ⁷Department of Cell Biology, Immunology and Physiology, University of Cordoba (UCO), Agrifood Campus of International Excellence, (ceiA³)., Cordoba, Spain, ⁸Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Spain, ⁹Department of Cell Biology, Physiology and Immunology, Maimonides Institute of Biomedical Research of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Cordoba, Cordoba, Spain, Cordoba, Spain, ¹⁰Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain/ CobiomicBioscience S.l, Cordoba, Spain, Cordoba, Spain
Background/Purpose: This study aims to:1- Characterize the circulating metabolomic signature in APS patients; 2- Investigate the role of hepatic involvement in the pathophysiology of APS;…
Abstract Number: 1741 • ACR Convergence 2025
Chronic JDM Plasma Proteomic Signature Reflects Inflammation from Immune and Tissue-resident Muscle and Skin
Marianne Kerski¹, Celine Berthier¹, Benjamin Klein¹, Li Chen², Christine Goudsmit², Sophia Matossian¹, Qinmengge Li³, Chioma Madubata⁴, Jessica Neely⁵, J. Michelle Kahlenberg¹ and Jessica Turnier⁶, ¹University of Michigan, Ann Arbor, MI, ²University of Michigan, Ann Arbor, ³University of Michigan, Ypsilanti, MI, ⁴UCSF, SF, CA, ⁵UCSF, San Francisco, CA, ⁶University of Michigan, Saline, MI
Background/Purpose: Juvenile dermatomyositis (JDM) and childhood-onset SLE (cSLE) are systemic autoimmune diseases characterized by overlapping yet distinct clinical manifestations and treatment responses. In this study,…
Abstract Number: 1702 • ACR Convergence 2025
Powerful and Accurate Case-Control Analysis of Spatially Resolved Molecular Data in Autoimmune Disease
Yakir Reshef¹, Lakshay Sood¹, Michelle Curtis¹, Laurie Rumker², DANIEL STEIN³, Mukta Palshikar¹, Saba Nayar⁴, Andrew Filer⁵, Anna Helena Jonsson⁶, ilya Korsunsky⁷ and Soumya Raychaudhuri⁷, ¹Brigham and Women's Hospital, Boston, ²Broad Institute, Boston, ³Harvard University, Boston, ⁴University of Birmingham, Birmingham, United Kingdom, ⁵The University of Birmingham, Birmingham, United Kingdom, ⁶University of Colorado School of Medicine, Aurora, CO, ⁷Brigham and Women's Hospital, Boston, MA
Background/Purpose: Autoimmune diseases such as rheumatoid arthritis (RA) involve complex spatial organization of immune and stromal cells within inflamed tissues. As spatial molecular profiling methods…
Abstract Number: 1181 • ACR Convergence 2025
Clinical Relevance of Tumor Necrosis Factor Superfamily Cytokines
Robert Corty¹, Gul Karakoc¹, Ahmad Jawdat², Hui Yu³, Jonathan Mosley⁴, Michael Stein¹ and Vivian Kawai⁵, ¹Vanderbilt University Medical Center, Nashville, TN, ²University of Alabama at Birmingham, Birmingham, ³University of Miami, Miami, ⁴UT Southwestern Medical Center, Dallas, ⁵University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: The tumor necrosis factor superfamily (TNFSF) includes 48 proteins involved in immune activation, inflammation, and cell death and represent an area of intense focus…
Abstract Number: 1000 • ACR Convergence 2025
A Deep-Learning Based Approach Uncovers Novel Mediators of Micro-RNA Restraint of Type-2 Immunity
Shaan Sekhon¹, Robin Kageyama², Neil Sprenkle³, Hannah Happ², Eric Wigton², Heather Pua³ and Mark Ansel², ¹University of California, San Francisco, Berkeley, ²University of California, San Francisco, San Francisco, ³Vanderbilt University, Nashville
Background/Purpose: MicroRNAs, such as miR-24 and miR-27, co-expressed within the Mirc11 and Mirc22 clusters, orchestrate a regulatory network critical to Th2 cell differentiation and cytokine…
Abstract Number: 0889 • ACR Convergence 2025
Potentially pathogenic memory CD4 T cells with a B cell helper phenotype expand in ACPA+ individuals during progression to rheumatoid arthritis
Ziyuan He¹, Marla Glass¹, Pravina Venkatesan², Alexandra Ferrannini³, Marie Feser⁴, Christy Bennett¹, David Boyle⁵, Kristen Demoruelle⁶, Kristine Kuhn⁷, Fan Zhang⁸, Thomas Bumol⁹, Ananda Goldrath³, Peter Skene³, V. Michael Holers¹⁰, Xiaojun Li¹, Adam Savage¹, Gary Firestein¹¹, Kevin Deane¹², Troy Torgerson¹³ and Mark Gillespie¹, ¹Allen Institute for Immunology, Seattle, WA, ²Allen Insitute, Seattle, WA, ³Allen Institute for Immunology, Seattle, ⁴University of Colorado Anschutz Medical Campus, Aurora, CO, ⁵UCSD, La Jolla, CA, ⁶University of Colorado Anschutz Medical Campus, Golden, CO, ⁷²⁰²² - ²⁰²³ / Adult/ University of Colorado, Aurora, CO, ⁸The University of Colorado, Aurora, CO, ⁹Allen Institute for Immunology, San Diego, CA, ¹⁰University of Colorado, Denver, CO, ¹¹University of California, San Diego, San Diego, CA, ¹²University of Colorado Denver Anschutz Medical Campus, Aurora, CO, ¹³Allen Institute for Immunology, Enumclaw, WA
Background/Purpose: Prior to the onset of clinically apparent inflammatory arthritis (IA)/synovitis (clinical RA), ACPA+ ‘at-risk’ individuals (ARI) show alterations in the abundance of effector T…
Abstract Number: 0795 • ACR Convergence 2025
Molecular Stratification of Rheumatoid Arthritis Patients by Multi-Omics Integration Reveals Disease Status and Predictors of Therapeutic Response
Ismael Sanchez-Pareja¹, Daniel Toro², Carlos Pérez Sánchez³, Laura muñoz-Barrera¹, Tomás Cerdó¹, Elena Moreno-Caño⁴, Sagrario Corrales¹, Lydia Formanti Alonso⁵, Rafaela Ortega-Castro⁶, Jerusalén Calvo⁵, Lourdes Ladehesa⁷, Concepción Aranda-Valera⁵, M Carmen Abalos-Aguilera⁸, Christian Merlo-Ruiz⁸, MARIA ANGELES AGUIRRE ZAMORANO¹, Marta Alarcon-Riquelme⁹, Alejandro Escudero Contreras⁵ and Chary López pedrera¹⁰, ¹Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Córdoba, Spain, ²GENYO / Karolinska Institutet, Granada / Stockholm, Spain, ³Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain/ CobiomicBioscience S.l, Cordoba, Spain, Cordoba, Spain, ⁴IMIBIC-Reina Sofia Hospital-University of Cordoba, Cordoba, Spain, Córdoba, Spain, ⁵IMIBIC / Reina Sofia Hospital / University of Cordoba, Córdoba, Spain, ⁶Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Andalucia, Spain, ⁷IMIBIC-Reina Sofia Hospital-University of Cordoba, Cordoba, Spain, Cordoba, Spain, ⁸Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Córdoba, Spain, ⁹Fundación Progreso y Salud, Andalusian Government, Granada, Spain, ¹⁰Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Spain
Background/Purpose: To characterize molecular profiles of RA patients through multi-omics integration and evaluate their associations with disease status and therapeutic response to csDMARDs, TNF inhibitors…
Abstract Number: 0329 • ACR Convergence 2025
Machine Learning-Based Model to Predict Rapid Structural Progression in Knee Osteoarthritis
Maria Fernanda Gonzalez Hernandez¹, Ignacio rego Pérez², Isabel Rodríguez Valle³, Jorge Vázquez García⁴, Vanesa Balboa⁵, Sara Relaño Fernández⁴, María C. de Andrés⁶, Lucía Lourido⁷, Valentina Calamia⁷, Rocio Paz González⁴, Patricia Quaranta⁷, Patricia Fernández-Puente⁴, Nicola Veronese⁸, Cristina Ruiz-Romero⁹, Natividad Oreiro¹⁰ and francisco J Blanco¹¹, ¹Instituto de Investigacion Biomedica de A Coruna (INIBIC), A coruña, Galicia, Spain, ²Department of Rheumatology, Rheumatology Research Group (GIR) Biomedical Re-search Institute (INIBIC), A Coruña, Spain, ³Instituto de Investigacion Biomedica de A Coruna (INIBIC), Coruña, Galicia, Spain, ⁴Instituto de Investigacion Biomedica de A Coruna (INIBIC), coruña, Spain, ⁵Grupo de Investigación de Reumatología (GIR). Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas, coruña, Spain, ⁶Instituto de Investigación Biomédica de A Coruña (INIBIC), Grupo de Investigación de Reumatología (GIR), A Coruña, Spain, ⁷Instituto de Investigacion Biomedica de A Coruna (INIBIC), coruna, Spain, ⁸Geriatric Unit, Department of Internal Medicine and Geriatrics, University of Palermo, palermo, Italy, ⁹Department of Rheumatology, Rheumatology Research Group (GIR) Biomedical Re-search Institute (INIBIC),, A Coruña, Spain, ¹⁰CHUAC, La Coruna, Spain, ¹¹INIBIC-University of A Coruña, A Coruña, Galicia, Spain
Background/Purpose: Osteoarthritis (OA) is the most common chronic joint disorder, characterized by structural cartilage and bone damage that often causes pain and disability. However, the…
Abstract Number: 1762 • ACR Convergence 2024
Multi-omic Analysis Defines Heterogeneous and Cell Specific Type I Interferon Signalling in Juvenile-onset SLE Patients Associated with Biomarkers of Cardiovascular Risk
Junjie Peng, Thomas McDonnell, Elizabeth Jury, Coziana Ciurtin and George Robinson, University College London, London, United Kingdom
Background/Purpose: Juvenile-onset systemic lupus erythematosus (jSLE) is an autoimmune disease characterised by chronic inflammation, multi-organ damage, and/or death. Despite their young age, jSLE patients have…
Abstract Number: 1771 • ACR Convergence 2024
Characterization of Pathogenic Immune Mechanisms in Oligoarticular Juvenile Idiopathic Arthritis Applying Single-cell Transcriptomics and Proteomics
Mireia Lopez Corbeto¹, yolanda Guillen², Irene Bonafonte³, Nuria Palau⁴, Raül Tortosa⁴, Estefanía Moreno Ruzafa¹, Antonio Julia⁵ and Sara Marsal⁶, ¹Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain, ²Imidomics, Inc, Barcelona, Spain, ³Berufserfahrung: Helmholtz Munich, Barcelona, Spain, ⁴Vall d´Hebron Hospital Research Institute, Rheumatology, Barcelona, Spain, ⁵Vall d'Hebron Hospital Research Institute, Barcelona, Spain, ⁶Vall Hebron Hospital Research Institute, Barcelona, Spain
Background/Purpose: Juvenile idiopathic arthritis (JIA) is a prevalent rheumatic disease in children, comprising seven subtypes. The most common, oligoarticular JIA (oJIA), accounts for 30-60% of…
Abstract Number: 1797 • ACR Convergence 2024
Characterizing Memory T Cell Subsets Associated with SLE Etiopathogenesis
Carol Nassar¹, Rene Quevedo², M. Teresa Ciudad², Zoha Faheem³, Kieran Manion⁴, Carolina Munoz-Grajales⁵, Michael Kim⁶, Dafna Gladman⁷, Murray Urowitz⁸, Zahi Touma¹, Tracy McGaha⁹ and Joan Wither⁶, ¹University of Toronto, Toronto, ON, Canada, ²Princess Margaret Cancer Centre, Toronto, ON, Canada, ³UHN, Toronto, ON, Canada, ⁴Toronto Western Hospital, Toronto, ON, Canada, ⁵UHN/TWH, Toronto, ON, Canada, ⁶University Health Network, Toronto, ON, Canada, ⁷University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁸Self employed, Toronto, ON, Canada, ⁹University Health Network, University of Toronto, Toronto, ON, Canada
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease associated with severe morbidity and mortality. Around 70% of SLE patients follow a relapsing-remitting pattern…
Abstract Number: 2096 • ACR Convergence 2024
A Model Based on Clinical and Molecular Data Predcits the Risk of Total Joint Replacement Progression in Knee OA Patients from the OAI
Ignacio Rego-Perez¹, Alejandro Duran-Sotuela², Jorge Vazquez-Garcia², Cristina Ruiz-Romero³, Valentina Calamia², Carlota Fraga-Seijas⁴, Vanesa Balboa-Barreiro⁵, Sara Relaño², María C. De Andrés², Lucia Lourido², Rocio Paz-Gonzalez², Patricia Quaranta², Patricia Fernández-Puente², Nicola Veronese⁶, Natividad Oreiro⁷ and francisco J Blanco⁸, ¹Instituto de Investigacion Biomedica de A Coruña-SERGAS, A Coruña, Spain, ²Servicio de Reumatología. Instituto de Investigación Biomédica de A Coruña (INIBIC). Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas, A Coruña, Spain, ³INIBIC - CHUAC, A Coruña, Spain, ⁴INIBIC, A Coruña, Spain, ⁵Unidad de Epidemiología Clínica y Bioeostadística. Instituto de Investigación Biomédica de A Coruña (INIBIC). Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC)., A Coruña, Spain, ⁶Geriatric Unit, Department of Internal Medicine and Geriatrics, University of Palermo, Via del Vespro, 141, 90127, Palermo, Italy, A Coruña, Spain, ⁷CHUAC, La Coruna, Galicia, Spain, ⁸INIBIC-University of A Coruña, A Coruña, Spain
Background/Purpose: There is a need to design models that predict the risk of total joint replacement (TJR) in patients with knee osteoarthritis (OA). Our aim…
Abstract Number: 2418 • ACR Convergence 2024
Identification of Co-expressed Molecular Markers That Predict Risk of Severe Flare in Patients with Systemic Lupus Erythematosus (SLE)
Matthew Linnik¹, Guilherme Rocha², David Gemperline³, Ernst Dow³, Christoph Preuss³, Helen Masson⁴, Olivia Ellis⁴, Ana Accioly³, Maja Hojnik⁵, Kira Rubtsova¹, Robert Benschop⁶, Mark Chambers⁷, Mark Genovese³ and Richard Higgs³, ¹Eli Lilly, San Diego, CA, ²Eli Lilly, Indianapolis, IN, ³Eli Lilly and Co, Indianapolis, IN, ⁴Eli Lilly and Co, San Diego, CA, ⁵Eli Lilly and Co., Indianapolis, IN, ⁶Eli Lilly and Company, Indianapolis, IN, ⁷Eli Lilly, Zionsville, IN
Background/Purpose: SLE flare is a clinically and regulatory relevant outcome, yet limited markers currently exist that predict its risk. We used baseline whole blood/serum samples…
Abstract Number: 2425 • ACR Convergence 2024
Ianalumab Induced Durable Depletion of Circulating B Cell Subsets and Associated Changes in B Cell and Neutrophil Transcriptomic and Proteomic Profiles in Patients with Systemic Lupus Erythematosus: 52-Week Treatment Results from a Phase 2 Trial
Marianna Rowlands¹, Thomas Dörner², Diego Saldana Miranda³, Justin McMullen³, Aida Santos da Costa³, Ulrike Sommer³, Rainer Hillenbrand³, Andre Nogueira da Costa³, Claire Bonal³, Isabelle Isnardi³, Edward Khokhlovich¹ and Stephen J Oliver³, ¹Biomedical Research, Novartis, Cambridge, MA, ²Department of Medicine, Rheumatology and Clinical Immunology,Charite Universitätsmedizin Berlin, Germany and DRFZ, Berlin, Berlin, Germany, ³Novartis Pharma AG, Basel, Switzerland
Background/Purpose: Ianalumab (VAY736), a B cell activating factor receptor (BAFFR) targeting mAb, depletes B cells via both antibody dependent cellular cytotoxicity and blockade of BAFF:BAFFR…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].